Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company 20/20 GeneSystems Inc.
DescriptionTissue-based in vitro diagnostic that uses layered immunohistochemistry (L-IHC) technology to predict patient response to drugs that target the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway
Molecular Target Protein kinase B (AKT) (AKT1) (PKB) (PKBA) ; Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsPredict patient response to treatment with Herceptin trastuzumab; Predict the efficacy of molecularly-targeted therapies to treat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today